Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/MZyExGCxRHc/242747.php
Sunday, 11 March 2012
NICE Recommends Unrestricted Access To 'Victrelis'� (boceprevir) When Used Within The Licensed Indication
In the UK, about 216,000 people suffer from a chronic infection of hepatitis C.5. The UK's National Institute for Health and Clinical Excellence (NICE) has just issued a Final Appraisal Determination (FAD) for recommending 'Victrelis'� (boceprevir), in combination with peginterferon alfa and ribavirin ('dual therapy'), as a treatment option for adults with genotype 1 chronic hepatitis C (CHC), with compensated liver disease who had no previous treatment, or for those who were unreceptive to other treatments...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment